Drug
Laquinimod clinical trials
Also written TV-5600.
- studies test it
- 15
- open now
- 1
- in phase 3
- 6
- first study started
- 2005
Keep track of what changes. Save the laquinimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
15 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Teva Branded Pharmaceutical Products R&D, Inc. (12) · Active Biotech AB (1) · Quan Dong Nguyen (1) · Teva Pharmaceutical Industries, Ltd. (1)
Studies
Open first, then newest update. How each study uses laquinimod is read from its arms, and is right about nine times in ten.
Testing it · 15
- Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION StudyRecruitingPhase 1Quan Dong NguyenNCT06161415Written as Laquinimod eye drops
- A Study of Laquinimod Eye-drops in Healthy ParticipantsCompletedPhase 1Active Biotech ABNCT05187403Written as Laquinimod
- A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus ArthritisCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT01085084Written as Laquinimod
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00605215Written as Laquinimod
- A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02284568Written as Laquinimod
- A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus NephritisCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT01085097Written as Laquinimod
- A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01047319Written as Laquinimod
- A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00988052Written as Laquinimod
- The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01707992Written as Laquinimod
- A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given TogetherCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02085863Written as laquinimod
- A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)WithdrawnPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01975298Written as Laquinimod
- Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00509145Written as Laquinimod
- A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of LaquinimodCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02215616Written as Laquinimod
- An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedPhase 2Teva Pharmaceutical Industries, Ltd.NCT00745615Written as Laquinimod
- Laquinimod Phase IIa Study in Active Crohn's DiseaseCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00737932Written as Laquinimod
Codes
What other systems call laquinimod · ClinicalTrials.gg INT004551
- MeSH (NLM) C476223laquinimodOne source NLM
- UNII (FDA) 908SY76S4GLAQUINIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q3487584laquinimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76569LaquinimodOne source FDA
- DrugBank DB06685One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C476223 | laquinimod | One source NLM |
| UNII (FDA) | 908SY76S4G | LAQUINIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3487584 | laquinimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76569 | Laquinimod | One source FDA |
| DrugBank | DB06685 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.